AI-Enabled Chest X-Ray Solution Elevates ICU and ER Care Pathways

By MedImaging International staff writers
Posted on 14 Sep 2023

Image: The qXR AI-enabled chest X-ray solution has received 510(k) FDA clearance under two critical findings (Photo courtesy of Qure.ai)

Pneumothorax (PTX), a condition where air collects in the pleural space and causes lung collapse, and pleura effusion (PE) in which fluid accumulates in the pleural cavity, create serious challenges in emergency rooms and intensive care units (ICUs). Now, an AI-enabled chest X-ray solution has received 510(k) FDA clearance to triage PTX and PE.

Qure.ai (Mumbai, MH, India) has secured 510(k) FDA clearance for its artificial intelligence-powered chest X-ray solution, known as qXR, specifically for the rapid identification of PTX and PE. This new clearance adds to the company's existing FDA-approved product range, which includes solutions like qXR-BT for breathing tube positioning, qER for emergency room head CT scans, and qER-Quant for head CT quantification software. qXR is designed to integrate seamlessly into current healthcare pathways, enhancing both ICU and ER operational efficiency. Clinical evaluations of qXR's effectiveness in identifying PTX have demonstrated outstanding accuracy in providing rapid passive notifications that take an average of just 10 seconds to reach healthcare staff.

Such rapid alerting capabilities make qXR-PTX-PE an invaluable asset for timely medical decision-making, particularly in critical settings like ICUs and emergency departments. The technology employs a training dataset gathered from multiple global sources and fits seamlessly into the current standard healthcare protocols, acting as a passive notification system for prioritizing tasks. A multi-center study assessing overlooked and incorrectly labeled chest X-ray findings for conditions like PTX and PE showed that the qXR algorithm achieved up to 96% sensitivity and 100% specificity.

“Speaking to physicians and hospital CEOs, we have heard the increasing need to reduce time to diagnosis." said Prashant Warier, CEO and Co-Founder of Qure. The FDA clearance of the qXR algorithm further demonstrates Qure’s commitment to addressing these challenges by optimizing healthcare delivery in time-sensitive settings like the ICU and ER.”

Related Links:
Qure.ai